CLAIMS

1. A graphene nanomaterial for use as a medicament,

wherein the graphene nanomaterial is selected from graphene nanofibers; and

wherein the graphene nanomaterial has a particle size distribution having a dn(90) of 0.60 μm or smaller in number of particle and a dv(90) of 80.00 μm or smaller in volume particle, as measured by laser diffraction particle analyzer.

2. The graphene nanomaterial for use as a medicament according to claim 1, wherein the BET specific surface area of the graphene nanomaterial is comprised between 100 and 500 m^2/g.

3. The graphene nanomaterial for use as a medicament according to claim 2, wherein the BET specific surface area of the graphene nanomaterial is between 300-350 m^2/g.

4. The graphene nanomaterial for use as a medicament according to claim 1, wherein the pore volume of the graphene nanomaterial is between 0.35-0.40 cm^3/g.

5. The graphene nanomaterial for use as a medicament according to claim 1, wherein the BET specific surface area of the graphene nanomaterial is between 300-350 m^2/g and the pore volume of the graphene nanomaterial is between 0.35-0.40 cm^3/g.

6. The graphene nanomaterial for use as a medicament according to any one of claims 1 to 5, wherein the impurities in the graphene nanomaterial is less than 0.01% by weight.

7. The graphene nanomaterial for use as a medicament according to any one of claims 1 to 6, in the treatment of wounds, scars, eczema, skin burns, skin ulcers or other skin lesions.

8. The graphene nanomaterial for use as a medicament according to claim 7, in the treatment of skin lesions produced by psoriasis, diabetes, cancer, infections, acne or decreased circulation of blood.

9. A pharmaceutical composition comprising a graphene nanomaterial and a pharmaceutically acceptable excipient,

o

wherein the graphene nanomaterial is selected from graphene nanofibers; and

wherein the graphene nanomaterial has a particle size distribution having a dn(90) of 0.60 μm or smaller in number of particle and a dv(90) of 80.00 μm or smaller in volume particle, as measured by laser diffraction particle analyzer.

10. The pharmaceutical composition according to claim 9, wherein the BET specific surface area of the graphene nanomaterial is comprised between 100 and 500 m^2/g.

11. The pharmaceutical composition as defined in claim 10, wherein the BET specific surface area of the graphene nanomaterial is between 300-350 m^2/g.

12. The pharmaceutical composition as defined in claim 9, wherein the pore volume of the graphene nanomaterial is between 0.35-0.40 cm^3/g.

13. The pharmaceutical composition as defined in claim 9, wherein the BET specific surface area of the graphene nanomaterial is between 300-350 m^2/g and the pore volume of the graphene nanomaterial is between 0.35-0.40 cm^3/g.

14. The pharmaceutical composition according to any one of claims 9 to 13, wherein the impurities in the graphene nanomaterial is less than 0.01% by weight.

15. The pharmaceutical composition according to any one of claims 9 to 14, wherein the composition is suitable for topical use.

16. The pharmaceutical composition according to claim 15, wherein the composition is in a form selected from a cream, an ointment, a microemulsion, a gel, an emulsion-gel, a paste, a foam, a tincture, a patch, a bandage, a membrane, a matrix or a transdermal delivery system.

17. The pharmaceutical composition according to claim 16, wherein the composition is a hydrogel or a cream.

o